心不全における心節機能障害:病理生理学から治療の視点への新たな視野
Isabella Fumarulo1,2, Elia Nunzio Maria Salerno1,2, Andrea De Prisco1,2
1Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Journal of cardiovascular development and disease
|August 27, 2025
まとめ
心不全 (HF) は,心筋と伝導組織の有害な改造を伴う. このレビューでは,高血圧性心房 (AV) ノード機能障害,その臨床的影響,および現在の/将来の治療法を調査します.
科学分野:
- 心臓病科
- 電気生理学
- 心不全 の 研究
背景:
- 心不全 (HF) は,心筋細胞と心伝導系の両方に悪影響を及ぼす心筋の再構築を伴う.
- 心房 (AV) ノード機能障害は,HFの一般的な合併症であり,伝導の遅延と不協和を引き起こします.
- HF患者の臨床結果はしばしばAVノード機能不全と関連していますが,その病理学は十分に研究されていません.
研究 の 目的:
- HFの文脈で AVノード機能障害の病理学を調査する.
- HF患者に対するAVノード機能障害の臨床的影響を解明する.
- HFにおけるAVノード機能不全の現在の治療戦略をレビューし,将来の潜在的な治療法を検討する.
主な方法:
- HFとAVノード病理に関する既存の研究の文献レビュー.
- HFとAVノード機能障害を結びつける病理学的メカニズムの分析.
- HFにおけるAVノード機能不全に関する臨床データの統合.
主要な成果:
- HFによる再構築は AV節の構造と機能に大きく影響します
- AV節の機能不全は不律とHFの悪い予後につながる.
- 現在の治療法は,HFにおけるAVノード特異的な病理に限られた有効性を提供しています.
結論:
- HFの AVノード病理学を理解することは,患者のアウトカムを改善するために不可欠です.
- AV節の機能障害を標的とした治療は,HFの潜在的な治療法です.
- HFにおける AVノード病理の効果的な治療法を開発するには,さらなる研究が必要です.
関連する概念動画
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Pathophysiology of Cardiac Performance
799
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
799


